Kohjin Bio Co.,Ltd. (177A) AI Stock Analysis

• Market Cap: ¥6.12B
• Dividend Yield: 1.62%
• Average Volume (3M): 3.64K
• Price to Earnings (P/E): 24.5
• Beta (1Y): 0.81
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: JP
• Employees: 159
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 15.18
• Shares Outstanding: 5,111,600
• 10 Day Avg. Volume: 4,170
• 30 Day Avg. Volume: 3,643
• PEG Ratio: 0.16
• Price to Book (P/B): 1.55
• Price to Sales (P/S): 1.72
• P/FCF Ratio: 318.77
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 67 Neutral
• Price Target: ¥1,299.00 ▼(-14.82% Downside)
• Action: Downgraded Date: 10/30/25
• Date: Action: Downgraded 10/30/25

Kohjin Bio Co., Ltd. shows strong financial performance with robust growth in revenue and profitability, supported by a stable balance sheet. However, the technical indicators suggest a bearish trend, which could pose short-term risks. The valuation is reasonable, with a moderate P/E ratio and dividend yield, making it attractive for long-term investors. The absence of recent earnings call insights or notable corporate events limits additional context.

Positive Factors

Balance sheet strength

A high equity ratio and low debt-to-equity indicate durable capitalization and financial flexibility. With ROE at 13.75%, the company efficiently deploys shareholder capital, giving it capacity to fund R&D, absorb shocks, or pursue strategic investments without overreliance on external financing.

High and sustainable margins

Robust gross and operating margins point to structural cost advantages or pricing power in core operations. Healthy EBIT/EBITDA margins support continued internal funding for growth and R&D, enhancing long-term competitiveness and resilience versus lower-margin peers.

Strong operating cash conversion

Operating cash flow exceeding net income shows efficient cash conversion from operations, reducing reliance on external funding. The positive free cash flow growth trend (7.52%) indicates improving cash generation capacity, which supports reinvestment, debt reduction, or shareholder returns over time.

Negative Factors

Mixed revenue trend

A negative revenue growth metric suggests recent top-line pressure or cyclicality that can impair long-term planning. Even if year-to-year figures vary, persistent or recurring declines reduce visibility on demand, constrain ability to scale fixed-cost investments, and heighten execution risk.

Low free cash flow relative to earnings

Very low FCF relative to net income indicates most reported profits are not translating into discretionary cash. This constrains capital allocation flexibility for capex, R&D, dividends or M&A, and may force dependence on external funding if investment needs rise.

Earnings (EBIT) volatility

Material EBIT volatility undermines predictability of operating performance and cash flow, complicating budgeting for R&D and growth initiatives. For a biotech firm, inconsistent core earnings can delay strategic programs and increase the chance of funding-driven dilution or cutbacks.

Kohjin Bio Co.,Ltd. Business Overview & Revenue Model

Company Description

Kohjin Bio Co., Ltd. manufactures and sells animal blood, sera, tissue culture media, agar media for microorganism tests, in-vitro diagnostic agents, and cosmetics. The company offers tissue culture mediums for virus and recombinant protein production, hybridoma, human lymphocyte culture, and insect cell lines; gas permeable cell culture bags and other materials; cryopreservation agent of cells; medium supplements; normal human cells; normal human cell mediums; ES cell mediums; in-vitro fertilization and early embryo culture kits; and other culture and related products, such as supplements, cell separation solutions, physiological salt solutions, and research reagents. The company also offers clinical microbiology culture mediums for gram positive cocci, gram negative bacteria, and susceptibility testing; general differential, anaerobic growth, and fungal mediums; tube mediums for confirmation and expansion; microbiology culture mediums for food, such as mediums for sterilization test, E. coli and coliform bacteria, staphylococcus spp., bacillus cereus, and vibrio parahaemolyticus; culture mediums for determining total viable cell count; and campylobacter and fungal mediums. In addition, the company offers normal human blood, serum, and plasma; pathological human serum; preserved animal blood; defibrinated and hemolyzed animal blood; animal serum and plasma; and other custom-designed products, such as eagle medium. Further, the company engages in the production and sale of laboratory animal, sale of medical equipment, trust of animal immunization and antibody preparation, and import and export of products and raw materials. The company was formerly known as Kohjin Co.,Ltd and changed its name to Kohjin Bio Co., Ltd. in 1989. The company was incorporated in 1981 and is based in Sakado, Japan.

How the Company Makes Money

null

Kohjin Bio Co.,Ltd. Financial Statement Overview

Summary

Kohjin Bio Co., Ltd. demonstrates robust financial health with strong growth in revenue and profitability, supported by a stable balance sheet. Effective leverage management and profitability metrics point to a solid operational footing. While cash flow generation is improving, enhancing free cash flow remains a focus area to bolster financial resilience further.

Income Statement

Kohjin Bio Co., Ltd. shows a strong revenue growth rate of 9.14% from 2024 to 2025 and a notable increase in net income, indicating positive momentum. The gross profit margin stands at 45.44%, and the net profit margin improved to 15.26%, reflecting efficient cost management. EBIT and EBITDA margins are also healthy, at 19.04% and 27.01%, respectively, suggesting robust profitability. However, the volatility in EBIT over the years indicates some operational fluctuations.

Balance Sheet

The company's balance sheet reflects stability with a solid equity ratio of 63.78%, indicating a strong capitalization. The debt-to-equity ratio has improved to 0.41, which suggests effective leverage management. Return on Equity (ROE) is impressive at 13.75%, demonstrating efficient use of shareholder funds. Despite these strengths, the company needs to maintain vigilance over its debt levels to ensure sustained financial stability.

Cash Flow

Operating cash flow is strong, with a good ratio of operating cash flow to net income at 1.15, indicating efficient cash conversion. Free cash flow to net income ratio is 0.04, showing modest free cash flow generation. However, the free cash flow growth rate of 7.52% indicates improvement, though further enhancements in cash generation would strengthen financial flexibility.

Breakdown	TTM	Mar 2025	Mar 2025	Mar 2023	Mar 2022
Income Statement
Total Revenue	5.18B	5.21B	4.77B	4.74B	3.95B
Gross Profit	2.31B	2.37B	1.88B	2.45B	2.04B
EBITDA	1.26B	1.41B	958.10M	1.44B	1.14B
Net Income	714.00M	794.76M	384.00M	829.79M	587.67M
Balance Sheet
Total Assets	9.17B	9.12B	6.64B	6.20B	5.60B
Cash, Cash Equivalents and Short-Term Investments	3.10B	3.15B	1.73B	1.46B	1.73B
Total Debt	1.99B	2.39B	2.47B	2.10B	2.23B
Total Liabilities	3.46B	3.34B	3.30B	3.18B	3.38B
Stockholders Equity	5.71B	5.78B	3.34B	3.02B	2.22B
Cash Flow
Free Cash Flow	0.00	28.05M	260.88M	-99.57M	559.44M
Operating Cash Flow	0.00	915.55M	823.68M	461.15M	762.98M
Investing Cash Flow	0.00	-1.09B	-577.35M	-575.46M	82.78M
Financing Cash Flow	0.00	1.38B	-1.35M	-172.21M	-360.17M

Kohjin Bio Co.,Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1525.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:177A, the sentiment is Negative. The current price of 1525 is above the 20-day moving average (MA) of 1219.55, above the 50-day MA of 1267.52, and below the 200-day MA of 1530.57, indicating a bearish trend. The MACD of -14.44 indicates Negative momentum. The RSI at 44.10 is Neutral, neither overbought nor oversold. The STOCH value of 22.24 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:177A.

Kohjin Bio Co.,Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
177A	67 Neutral	¥6.12B	24.52	―	1.62%	―	―
4978	56 Neutral	¥16.02B	120.78	―	―	1.24%	-33.41%
7774	54 Neutral	¥24.81B	-34.16	―	―	-5.65%	-469.19%
4974	52 Neutral	¥138.12B	-8.84	―	2.18%	-0.16%	-802.20%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
7776	49 Neutral	¥12.00B	-8.85	―	―	-42.49%	-2.37%
4599	43 Neutral	¥18.55B	-11.30	―	―	―	11.34%